Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: CROSSJECT

Market Cap 105M 122M 96.94M 90.75M 170M 11.57B 173M 1.15B 447M 5.63B 457M 447M 19.5B P/E Ratio 2026 *
4.71x
P/E Ratio 2027 * 3.72x
Enterprise Value 87.29M 101M 80.44M 75.31M 141M 9.6B 143M 954M 371M 4.67B 379M 371M 16.18B EV / Sales 2026 *
1.44x
EV / Sales 2027 * 1.38x
Free-Float
89.86%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 07/08/2001
Director of Finance/CFO - 24/03/2026
Corporate Officer/Principal - 19/08/2024
Director TitleAgeSince
Chairman 67 25/06/2009
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-3.77%-4.20%-20.02%-73.58% 91.64M
+0.11%+4.08%+98.89%+37.81% 87.79M
Average -1.83%-0.06%+39.43%-17.89% 89.72M
Weighted average by Cap. -1.87%-0.15%+38.16%-19.08%

Financials

2026 *2027 *
Net sales 60.8M 70.33M 56.03M 52.46M 98.36M 6.69B 99.79M 664M 258M 3.26B 264M 258M 11.27B 42.3M 48.93M 38.98M 36.5M 68.43M 4.65B 69.43M 462M 180M 2.27B 184M 180M 7.84B
Net income 28.3M 32.73M 26.08M 24.42M 45.78M 3.11B 46.45M 309M 120M 1.52B 123M 120M 5.25B 7.75M 8.96M 7.14M 6.69M 12.54M 853M 12.72M 84.7M 32.92M 415M 33.64M 32.92M 1.44B
Net Debt -17.9M -20.7M -16.5M -15.44M -28.96M -1.97B -29.38M -196M -76.04M -959M -77.69M -76.04M -3.32B -47M -54.36M -43.32M -40.55M -76.04M -5.17B -77.14M -514M -200M -2.52B -204M -200M -8.71B
Logo CROSSJECT
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!